Oclacitinib vs prednisolone for canine atopic dermatitis — POSSIBLE (the treatment made no difference on most measures)

In dogs with atopic dermatitis, does oclacitinib vs prednisolone give equivalent itch and lesion control?

Shelf #271 · gate-verified and displayed under the developer's blinded-trial rule

POSSIBLE (the treatment made no difference on most measures): In the one head-to-head trial, oclacitinib and prednisolone controlled pruritus and dermatitis to a similar degree over 28 days. In Gadeyne 2014 (123 client-owned dogs with allergic dermatitis in Australia, single-masked randomised trial), both treatments had a rapid onset of efficacy within 4 hours, and the mean reductions in owner pruritus scores and veterinarian dermatitis scores were not significantly different between treatments except on day 14, when reductions were more pronounced for oclacitinib (P = 0.0193 for owner pruritus scores; P = 0.0252 for veterinarian dermatitis scores); adverse events were reported with similar frequency in both groups. This shelf is a swap for topic #274: the assigned #274 anchor (Steffan 2006) proved at the gate to be a systematic review and meta-analysis, not the blinded ciclosporin vs prednisolone trial programme it was described as, so the swap order in the build brief was followed. With a single single-masked trial, no placebo arm, and no noninferiority margin stated in the record, equivalence is POSSIBLE, not proven. Drafted Nov 10, 2026 (VetMed build, topic #271); all figures from abstracts fetched and verified at drafting.

Gadeyne 2014: oclacitinib vs prednisolone — score reductions not significantly different except at day 14, favouring oclacitinib

Single-masked, randomised, controlled clinical trial vs prednisolone (28 days)

Who: Dogs: client-owned dogs (n = 123) in Australia with a presumptive diagnosis of allergic dermatitis and moderate to severe pruritus as assessed by the pet owner, in a single-masked, controlled clinical trial with a randomized complete block design — oclacitinib 0.4–0.6 mg/kg orally twice daily for 14 days, then once daily, or prednisolone 0.5–1.0 mg/kg once daily for 6 days, then every other day, for 28 days. Owners assessed pruritus and veterinarians assessed dermatitis on an enhanced visual analog scale at all time points.

Result: Both treatments produced a rapid onset of efficacy within 4 hours. The mean reductions in pruritus and dermatitis scores were not significantly different between the treatments except on day 14, when reductions were more pronounced for oclacitinib than prednisolone (P = 0.0193 for owner pruritus scores; P = 0.0252 for veterinarian dermatitis scores). Adverse events were reported with similar frequency in both groups. The record concludes both treatments provided rapid, effective and safe control of pruritus associated with allergic dermatitis, with substantial improvement in pruritus reported by owners and dermatitis reported by veterinarians.

Watch out: The diagnosis was presumptive allergic dermatitis (not confirmed atopic dermatitis in every dog), masking was single (MeSH: Single-Blind Method), there was no placebo arm, and the record states no prespecified noninferiority margin — 'not significantly different' in one 28-day trial is consistent with equivalence but does not prove it. Steroid adverse effects that matter in practice often emerge beyond 28 days or with repeated courses, which this trial cannot assess.

Gadeyne C, Little P, King VL, Edwards N, Davis K, Stegemann MR. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014;25(6):512-8, e86. PMID: 25109820. Registry ID: none in the record. MeSH: Administration, Oral · Animals · Australia · Dermatitis, Atopic · Dermatologic Agents · Dog Diseases · Dogs · Drug Administration Schedule · Female · Glucocorticoids · Male · Prednisolone · Pruritus · Pyrimidines · Single-Blind Method · Sulfonamides · Treatment Outcome

Synthesis: one single-masked head-to-head — similar 28-day control, equivalence not formally proven

Synthesis

Who: Synthesis of the card above: Gadeyne 2014 (single-masked randomised controlled trial, 123 dogs). This shelf rests on that one trial.

Result: For a dog whose itch needs controlling now, the trial supports oclacitinib as a working alternative to a short prednisolone course over 28 days: onset within 4 hours in both groups, no significant difference in score reductions at any point except day 14 (favouring oclacitinib), and similar adverse-event frequency. What it does not supply is a formal equivalence proof, a placebo reference, or any evidence about longer or repeated use of either drug.

Watch out: Single-trial, single-masked shelf — hence POSSIBLE. The swap history is part of this shelf's record: it replaces topic #274 (ciclosporin vs prednisolone), whose named anchor failed the gate as a systematic review/meta-analysis rather than a trial; the genuine blinded prednisolone-controlled ciclosporin trial in the literature is Olivry 2002 (PMID: 11972891), which a future #274 pack could be built on if the developer prefers that topic restored.

Synthesis of Gadeyne C et al. PMID: 25109820. Registry ID as on the individual card.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.